Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Zentalis Pharmaceuticals Llc

Healthcare US ZNTL

3.75USD
0.23(6.53%)

Last update at 2026-06-12T20:00:00Z

Day Range

3.483.77
LowHigh

52 Week Range

9.5630.53
LowHigh

Fundamentals

  • Previous Close 3.52
  • Market Cap842.22M
  • Volume889940
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-207.44701M
  • Revenue TTM40.56M
  • Revenue Per Share TTM0.59
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.43

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -221.30000M -164.55900M -118.10400M -46.36300M -23.42800M
Minority interest -0.30700M -7.36800M 24.80M 6.82M 7.54M
Net income -220.83100M -164.26200M -118.54800M -46.37800M -21.06700M
Selling general administrative 54.55M 40.94M 33.89M 8.46M 4.88M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.01M
Reconciled depreciation 1.43M 0.54M 0.16M 0.11M 0.05M
Ebit -227.28700M -216.54200M -118.78700M -46.84500M -23.78300M
Ebitda -233.27400M -268.52500M -119.47000M -46.73400M -23.73200M
Depreciation and amortization -5.98700M -51.98300M -0.68300M 0.11M 0.05M
Non operating income net other -16.28200M 49.75M - - -
Operating income -227.28700M -216.54200M -118.78700M -46.84500M -23.78300M
Other operating expenses 227.29M 216.54M 118.79M 46.84M 23.80M
Interest expense 2.58M 110.05M 2.23M 1.20M 0.00000M
Tax provision -0.46900M -0.29700M 0.44M 0.01M 0.00400M
Interest income - - - 0.50M 0.35M
Net interest income - - - 0.50M 0.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.46900M -0.29700M 0.44M 0.01M 0.00400M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.01M
Total operating expenses 227.29M 216.54M 118.79M 46.84M 23.80M
Cost of revenue - - - - -
Total other income expense net 5.99M 51.98M 0.68M 0.48M 0.35M
Discontinued operations - - - - -
Net income from continuing ops -220.83100M -164.26200M -118.54800M -46.37800M -23.43200M
Net income applicable to common shares -236.80600M -158.72500M -117.84100M -45.66300M -23.43200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 562.03M 539.31M 454.51M 365.56M 102.66M
Intangible assets - - - 8.80M 8.80M
Earning assets - - - - -
Other current assets 13.80M 14.56M 10.88M 6.18M 1.50M
Total liab 124.64M 105.29M 90.03M 32.18M 19.06M
Total stockholder equity 437.28M 434.02M 364.48M 333.38M 76.78M
Deferred long term liab - - - - 0.84M
Other current liab 51.54M 45.40M 30.90M 19.04M 9.83M
Common stock 0.07M 0.06M 0.04M 0.04M 0.03M
Capital stock 0.07M 0.06M 0.04M 0.04M 0.03M
Retained earnings -888.55600M -596.36500M -359.55900M -200.83400M -82.99300M
Other liab - 3.47M 1.62M 2.48M 4.16M
Good will 3.74M 3.74M 3.74M 3.74M 3.74M
Other assets - 12.35M 9.67M 4.30M 3.22M
Cash 28.04M 43.07M 59.71M 54.95M 82.42M
Cash and equivalents - - - - -
Total current liabilities 69.37M 56.65M 43.94M 28.60M 14.90M
Current deferred revenue 0.28M - - - -
Net debt 17.73M 2.10M -13.80200M -52.95200M -81.64100M
Short term debt 2.62M - 1.45M 0.90M 0.78M
Short long term debt - - - - -
Short long term debt total 45.77M 45.17M 45.91M 2.00M 0.78M
Other stockholder equity 1323.58M 1031.68M 724.12M 534.13M 159.74M
Property plant equipment - 7.71M 8.15M 3.62M 2.84M
Total current assets 496.72M 451.93M 350.77M 345.10M 84.07M
Long term investments 0.00000M 21.21M 37.49M - -
Net tangible assets - 433.80M 360.22M 296.05M -92.64200M
Short term investments 454.88M 394.30M 280.17M 283.55M -
Net receivables - - 4.44M 0.42M 0.14M
Long term debt - - - - -
Inventory - - -4.43900M - -
Accounts payable 14.93M 11.25M 11.59M 8.66M 4.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 0.22M 0.53M 24.80M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.19M -1.35300M -0.12500M 0.04M -0.16700M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.04M 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -596.36500M -359.55900M -200.83400M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.82M 12.35M 2.63M 4.30M 3.22M
Deferred long term asset charges - - - - -
Non current assets total 65.31M 87.38M 103.74M 20.45M 18.59M
Capital lease obligations 43.15M 45.17M 45.91M 2.00M 0.78M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -111.63200M 2.31M -284.83200M -0.35200M -0.22700M
Change to liabilities 15.53M 13.92M 14.31M 7.12M 0.98M
Total cashflows from investing activities -114.18000M -18.11500M -284.83200M -0.35200M -0.22700M
Net borrowings - - - - -
Total cash from financing activities 261.04M 178.52M 360.44M 81.83M 9.47M
Change to operating activities -2.27500M 2.23M -6.18600M -1.39300M -1.90100M
Net income -237.11300M -166.09300M -118.54800M -46.37800M -23.43200M
Change in cash -16.88800M 6.31M -11.21800M 42.34M -15.00600M
Begin period cash flow 62.58M 56.27M 67.49M 25.15M 40.16M
End period cash flow 45.70M 62.58M 56.27M 67.49M 25.15M
Total cash from operating activities -163.75100M -154.09300M -86.82500M -39.14300M -24.25100M
Issuance of capital stock 261.04M 179.67M 342.01M 81.88M 9.47M
Depreciation 1.43M 0.54M 0.16M 0.11M 0.05M
Other cashflows from investing activities - -14.32000M - - -
Dividends paid - - - - -
Change to inventory - 0.88M -5.51900M -1.50800M -1.86100M
Change to account receivables - 0.41M -0.27700M 0.78M -0.25400M
Sale purchase of stock 261.04M 179.67M 346.21M 81.88M 9.47M
Other cashflows from financing activities -114.18000M -1.14600M 32.65M 81.83M 9.46M
Change to netincome 62.41M 46.38M 23.01M -0.09800M 0.31M
Capital expenditures 2.55M 6.11M 0.76M 0.35M 0.23M
Change receivables - 0.41M -0.27700M - -
Cash flows other operating -2.27500M -50.16400M -6.18600M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -16.88800M 6.31M -11.21800M - -
Change in working capital 13.25M 16.56M 7.84M 6.51M -1.17800M
Stock based compensation 46.84M 35.74M 23.15M 0.62M 0.31M
Other non cash items 12.61M -38.37600M 0.56M -0.71500M -2.36500M
Free cash flow -166.29900M -160.20000M -87.58300M -39.49500M -24.47800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ZNTL
Zentalis Pharmaceuticals Llc		 0.23 6.53% 3.75 - - - 2.18 -2.0265
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Zentalis Pharmaceuticals Llc

1359 Broadway, New York, NY, United States, 10018

Key Executives

Name Title Year Born
Dr. Kimberly Lynn Blackwell M.D. CEO & Director 1969
Mr. Cameron S. Gallagher M.B.A. Co-Founder, Pres & Director 1970
Dr. Kevin D. Bunker Ph.D. Co-Founder & Chief Scientific Officer 1972
Ms. Melissa B. Epperly M.B.A. CFO & Treasurer 1978
Adam Levy Sr. VP of Investor Relations NA
Ms. Andrea Paul J.D. Gen. Counsel & Corp. Sec. 1981
Dr. Meena Rao Ph.D. Sr. VP of Regulatory Affairs & Quality Assurance NA
Dr. Carrie Brownstein M.D. Chief Medical Officer 1970
Dr. Mark Lackner Ph.D. Chief Translational Officer & Head of Biomarker Strategy 1967
Dr. Kimberly Lynn Blackwell M.D. CEO & Director 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions